FDA MedWatch Drug Alerts
September 3rd, 2009
The U.S. FDA warns the public that there is a potential for stolen long-acting insulin Levemir, produced by Novo Nordisk Inc, to still be active on the market. Based on the FDA’s evidence, their proof suggests that the stolen insulin was improperly stored and handled, leaving the public vulnerable to risk. Many patients have informed the FDA of adverse side effects they experienced after using a vial from the stolen group, their glucose levels were incorrectly managed.
August 19th, 2009
The U.S. FDA and Roche have informed healthcare practitioners that patients being treated with CellCept, have reported cases of Pure Red Cell Aplasia, also known as PRCA.
August 11th, 2009
The National Heart, Lung and Blood Institute (NHLBI) has halted a clinical trial involving drug treatment tests for pulmonary hypertension in adults who suffer from sickle cell disease.
August 10th, 2009
The US FDA recently issued a recommendation advising that certain pharmaceutical components used in the production or composition of drug products should be tested for melamine.
August 7th, 2009
The US FDA has advised healthcare practitioners and consumers of current safety information with regard to body building and increase muscle mass products, these products are commonly described as a substitute for anabolic steroids (used to increase muscle mass and strength), available both online and in retail establishments.
August 7th, 2009
The FDA’s laboratory analysis discovered sulfoaildenafil, an analog of sildenafil. Sildenafil is a key ingredient in the FDA-approved drug for erectile dysfunction, which makes Steam an unsanctioned drug.
August 7th, 2009
The US FDA requires TNF blockers to include firm detailed warnings in the prescribing information.
August 7th, 2009
The US FDA cautions consumers of the harmful effects Clarcon skin products are having on the skin. They urge consumers to cease all usage of Clarcon Biological Chemistry Laboratory skin sanitizer or protectants, because of hazardous bacteria.
August 7th, 2009
The US FDA has announced and advised healthcare providers of modifications to the well-known drug names for Botox / Botox Cosmetics, Dysport and Myobloc. These modifications are in the hopes to provide healthcare professionals advice on how to avoid medication inaccuracy, and reinforce individual potency. The modifications are also to provide additional information to patients, family members and caregivers.
August 7th, 2009
Recently, Ranbaxy Pharmaceuticals Inc. announced their voluntary recall of all Nitrofurantoin Capsules lot (USP 100 mg capsules), that currently exist on the U.S. marke
